Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

[1]  Y. Liou,et al.  Switching From Clozapine to Zotepine in Patients With Schizophrenia: A 12-Week Prospective, Randomized, Rater Blind, and Parallel Study , 2013, Journal of clinical psychopharmacology.

[2]  Bernadette A. Thomas,et al.  Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[3]  C. Correll,et al.  Body Weight and Metabolic Adverse Effects of Asenapine, Iloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder , 2012, CNS Drugs.

[4]  L. Hartling,et al.  Antipsychotics in Adults With Schizophrenia: Comparative Effectiveness of First-Generation Versus Second-Generation Medications , 2012, Annals of Internal Medicine.

[5]  H. Möller,et al.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance , 2012, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[6]  Georgia Salanti,et al.  Indirect and mixed‐treatment comparison, network, or multiple‐treatments meta‐analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool , 2012, Research synthesis methods.

[7]  Anna Chaimani,et al.  Using network meta‐analysis to evaluate the existence of small‐study effects in a network of interventions , 2012, Research synthesis methods.

[8]  N. Khin,et al.  Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration. , 2012, The Journal of clinical psychiatry.

[9]  D. Kelly,et al.  The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements , 2012 .

[10]  Marc De Hert,et al.  Metabolic and cardiovascular adverse effects associated with antipsychotic drugs , 2012, Nature Reviews Endocrinology.

[11]  J. Csernansky,et al.  Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. , 2011, The Journal of clinical psychiatry.

[12]  Andrea Cipriani,et al.  Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis , 2011, The Lancet.

[13]  Alex J Sutton,et al.  Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study , 2011, BMJ : British Medical Journal.

[14]  Georgia Salanti,et al.  Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. , 2011, Journal of clinical epidemiology.

[15]  B. Everitt,et al.  Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP) , 2010, Acta psychiatrica Scandinavica.

[16]  S. Duffull,et al.  Amisulpride Overdose Is Frequently Associated With QT Prolongation and Torsades de Pointes , 2010, Journal of clinical psychopharmacology.

[17]  R. Baldessarini,et al.  International consensus study of antipsychotic dosing. , 2010, The American journal of psychiatry.

[18]  S Dias,et al.  Checking consistency in mixed treatment comparison meta‐analysis , 2010, Statistics in medicine.

[19]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. , 2009, Journal of clinical epidemiology.

[20]  Julian P T Higgins,et al.  A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. , 2009, Journal of clinical epidemiology.

[21]  S. Leucht,et al.  How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials , 2009, Molecular Psychiatry.

[22]  E. Stewart,et al.  Faculty Opinions recommendation of Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. , 2009 .

[23]  J. Geddes,et al.  Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis , 2009, The Lancet.

[24]  John M Davis,et al.  A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. , 2009, The American journal of psychiatry.

[25]  John M. Davis,et al.  Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis , 2009, The Lancet.

[26]  P. Dazzan,et al.  Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review , 2008, Psychological Medicine.

[27]  Georgia Salanti,et al.  Evaluation of networks of randomized trials , 2008, Statistical methods in medical research.

[28]  Christian R. Dolder,et al.  Paliperidone for schizophrenia. , 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[29]  J. Kane,et al.  Haloperidol versus chlorpromazine for schizophrenia. , 2008, The Cochrane database of systematic reviews.

[30]  Deborah M Caldwell,et al.  Validity of indirect comparisons in meta-analysis , 2007, The Lancet.

[31]  Peter B. Jones,et al.  Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). , 2006, Archives of general psychiatry.

[32]  W. Fleischhacker,et al.  Comparative efficacy of antipsychotics in the treatment of schizophrenia: A critical assessment , 2005, Schizophrenia Research.

[33]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[34]  Rachel Churchill,et al.  Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. , 2004, Journal of clinical epidemiology.

[35]  G. Lu,et al.  Combination of direct and indirect evidence in mixed treatment comparisons , 2004, Statistics in medicine.

[36]  S. Leucht,et al.  New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis , 2003, The Lancet.

[37]  I. Glick,et al.  A meta-analysis of the efficacy of second-generation antipsychotics , 2003, Schizophrenia Research.

[38]  N Freemantle,et al.  Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis , 2000, BMJ : British Medical Journal.

[39]  H. Sauer,et al.  Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology – a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist , 1998, Psychopharmacology.

[40]  A Whitehead,et al.  Borrowing strength from external trials in a meta-analysis. , 1996, Statistics in medicine.

[41]  D. Klein.  Diagnosis and Drug Treatment of Psychiatric Disorders , 1969, British Journal of Psychiatry.

[42]  J. Overall,et al.  The Brief Psychiatric Rating Scale , 1962 .

[43]  T. Stanley,et al.  Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study , 2015 .

[44]  C. Adams,et al.  Haloperidol dose for the acute phase of schizophrenia. , 2013, The Cochrane database of systematic reviews.

[45]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration , 2013 .

[46]  J. Ballenger.  Comparative Mortality Associated With Ziprasidone and Olanzapine in Real-World Use Among 18,154 Patients With Schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC) , 2012 .

[47]  Andrea Cipriani,et al.  Imputing missing standard deviations in meta-analyses can provide accurate results. , 2006, Journal of clinical epidemiology.

[48]  S. Leucht,et al.  Perphenazine for schizophrenia. , 2005, The Cochrane database of systematic reviews.

[49]  A. Wieck,et al.  Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. , 2004 .

[50]  S. Lawrie,et al.  Haloperidol versus placebo for schizophrenia. , 2001, The Cochrane database of systematic reviews.

[51]  C. Adams,et al.  Chlorpromazine versus placebo for schizophrenia. , 2000, The Cochrane database of systematic reviews.

[52]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[53]  E. Rüther,et al.  A Double Blind Comparison of Amisulpride vs. Haloperidol in Acute Schizophrenic Patients , 1985 .

[54]  B. Jones,et al.  Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. , 1980, The American journal of psychiatry.